Renzo Cecere
-
Thomas Smeenk provides an update on Hemostemix’s ACP-01 stem cell treatment for heart disease
Peter Clausi interviews Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenk about an…
-
Hemostemix adds depth and strength to its scientific bench on the road to commercialization
Since we last covered Hemostemix where they released the promising results of their retrospective study of heart disease…
